• Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Annexin Pharmaceuticals

13,00 SEK

0,00 %

Mindre end 1K følgere

ANNX

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Dividend
Investorkonsensus
Sammenligne
0,00 %
-13,04 %
-10,34 %
-34,34 %
-42,98 %
-62,54 %
-77,44 %
-86,34 %
-95,93 %

Annexin Pharmaceuticals is a biotechnology company developing the drug candidate ANXV, based on the protein Annexin A5, for the treatment of diseases such as vascular damage, inflammation and certain cancers. The company's partners are healthcare providers and biopharmaceutical companies and the business is aimed at global markets through research and licensing collaborations. The company was founded in 2014 and is headquartered in Stockholm, Sweden.

Læs mere
Markedsværdi
91,77 mio. SEK
Aktieomsætning
219,61 t SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
Alle
Selskabsmeddelelser
ViserAlle indholdstyper

Finanskalender
16.7
2026

Delårsrapport Q2'26

22.10
2026

Delårsrapport Q3'26

11.2
2027

Årsrapport '26

Pressemeddelelse5.6.2026, 06.30

Annexin Pharmaceuticals to present at Aktiedagarna in Stockholm on June 10

Annexin Pharmaceuticals
Selskabsmeddelelse3.6.2026, 20.50

Annexin resolves a rights issue of approximately SEK 20 million, secured to approximately 60 percent, with an overallotment option of up to approximately SEK 5 million

Annexin Pharmaceuticals
Pressemeddelelse21.5.2026, 06.30

Annexin investigates a three-day ANXV treatment regimen in patients with RVO

Annexin Pharmaceuticals

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse11.5.2026, 06.30

Annexin receives clinical trial approval in Germany, widening patient recruitment in the NEXUS study

Annexin Pharmaceuticals
Pressemeddelelse24.4.2026, 07.40

Redeye: Annexin Pharmaceuticals (Q1 review): Study on track

Annexin Pharmaceuticals
Pressemeddelelse22.4.2026, 06.30

Annexin accelerates patient recruitment – five patients treated

Annexin Pharmaceuticals
Selskabsmeddelelse13.4.2026, 11.29

Annexin secures financing through bridge loan facility and plans a rights issue of approximately SEK 20 million during the summer of 2026

Annexin Pharmaceuticals
Pressemeddelelse6.2.2026, 14.17

Redeye: Annexin Pharmaceuticals (Q4 review): Phase II study away, with positive initial results

Annexin Pharmaceuticals
Selskabsmeddelelse4.2.2026, 13.36

Favourable findings in Annexin’s ongoing Phase 2a study in Diabetic Retinopathy and Retinal Vein Occlusion

Annexin Pharmaceuticals
Selskabsmeddelelse29.1.2026, 07.30

Annexin engages Pareto Securities as liquidity provider

Annexin Pharmaceuticals
Pressemeddelelse19.12.2025, 09.25

BioStock: Annexin has laid the foundation for continued clinical development

Annexin Pharmaceuticals
Pressemeddelelse18.12.2025, 11.30

Interview and webinar published on Annexin's ongoing Phase 2a study in diabetic retinopathy and retinal vein occlusion

Annexin Pharmaceuticals
Pressemeddelelse9.12.2025, 06.50

BioStock: Annexin advances phase IIa study by initiating patient treatment

Annexin Pharmaceuticals
Pressemeddelelse5.12.2025, 07.30

First patients treated in Annexin's Phase 2a study in diabetic retinopathy and RVO

Annexin Pharmaceuticals
Pressemeddelelse19.11.2025, 12.32

BioStock: Video from Annexin Pharmaceutical's presentation at BioStock Life Science Summit 2025

Annexin Pharmaceuticals
Pressemeddelelse28.10.2025, 10.47

Redeye: Annexin (Q3’25 Review) - Clinical study in focus

Annexin Pharmaceuticals
Pressemeddelelse23.10.2025, 08.29

BioStock: Annexin's Q3: Establishment of Medical Advisory Board and focus on ophthalmology

Annexin Pharmaceuticals
Pressemeddelelse15.10.2025, 06.30

Annexin Pharmaceuticals selected to present at the Eyecelerator conference and meets with the Medical Advisory Board in Orlando

Annexin Pharmaceuticals
Pressemeddelelse18.9.2025, 06.25

BioStock: Annexin strengthens operations with Medical Advisory Board

Annexin Pharmaceuticals
Pressemeddelelse16.9.2025, 06.30

Annexin appoints world-leading ophthalmology experts to Medical Advisory Board

Annexin Pharmaceuticals